News | Stereotactic Body Radiation Therapy (SBRT) | February 12, 2021

 

Demand for next-gen brain tumor treatment technology exceeds expectations

ZAP Surgical Systems, Inc. announced 18 new system orders in 2020 for its recently commercialized ZAP-X Gyroscopic Radiosurgery platform.

February 12, 2021 — ZAP Surgical Systems, Inc. announced 18 new system orders in 2020 for its recently commercialized ZAP-X Gyroscopic Radiosurgery platform. The news marks an extraordinary increase in year-over-year order volume. Having recently launched a robust global infrastructure, orders originated from both hospital and free-standing centers in the United States, Germany, Italy, Switzerland, Japan and other countries.

“ZAP started 2020 with highly ambitious goals. By mid-year however, COVID dashed many hopes of achieving those original plans,” said Richard Rosene, executive vice president of global sales and marketing. “The market has obviously responded favorably to ZAP-X, and we’re incredibly grateful to have surpassed global pre-pandemic sales targets for the year. Given the COVID challenges faced by our customers in the hospital and private sectors, it’s a remarkable accomplishment.”

Stereotactic radiosurgery (SRS) is a well-studied and effective treatment for many brain cancers including primary and metastatic brain tumors. Considered an alternative to surgery for many such indications, SRS is an outpatient procedure that often provides equivalent outcomes, yet requires no surgical incision, and little to no patient recovery period.

ZAP-X is also acclaimed for being the first and only vault-free SRS delivery system, thus typically eliminating the need for costly shielded radiation treatment rooms. Deploying a modern linear accelerator to produce radiation, ZAP-X also obviates the regulatory and heightened security requirements for providers to host live radioactive isotopes within their clinics.

“Historically, the associated costs and complexities of delivering SRS meant the vast majority of radiosurgery occurred primarily in the largest, most well-funded academic hospitals. We estimate this paradigm has left nearly 90% of potential SRS patient candidates without adequate access,” said John Adler, M.D., CEO of ZAP Surgical Systems, and professor emeritus of neurosurgery and radiation oncology at Stanford University. “ZAP-X has effectively broken down those barriers to now make it feasible to bring world-class SRS to more patients in more places.”

For more information: www.zapsurgical.com

Related Brain Radiotherapy Content:

VIDEO: Use of a Fully Self-contained Brain Radiotherapy System

New Radiotherapy and Medical Physics Technology at AAPM 2019

 


Related Content

News | ASTRO

Sept. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has named Siemens Healthineers the inaugural ...

Time September 29, 2026
arrow
News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | Molecular Imaging

Sept. 22, 2026 — Blue Earth Diagnostics, a part of the Bracco Group, has announced new research examining how precision ...

Time September 23, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026 — Leo Cancer Care and GE HealthCare have announced that the two companies intend to work together on GE ...

Time September 11, 2026
arrow
News | ASTRO

Sept. 9, 2026 — The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will take place Sept. 26 to 30 ...

Time September 11, 2026
arrow
News | Radiation Oncology

Sept. 2, 2026 — Children with one of the deadliest forms of brain cancer may benefit from an additional course of ...

Time September 03, 2026
arrow
News | Radiation Therapy

Aug. 13, 2026 — An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence ...

Time August 17, 2026
arrow
News | Prostate Cancer

Aug. 13, 2026 — Artera has announced the enrollment of the first patient in its DIRECT-AI registry study, marking the ...

Time August 14, 2026
arrow
Subscribe Now